A young pharmaceutical startup has signed an agreement with a local non-profit to share research space.
The Hamner Institutes for Health Sciences will host Ascletis, which works to develop new treatments or cancer and infectious diseases by licensing the rights of drugs in late-stage clinical trials, in its RTP headquarters.
Ascletis, which is been backed by Chinese investors, maintains a 30,000-square-foot facility in Hangzhou, China. Prior to this new joint venture, the company had not established a U.S. research base. In addition to licensing experimental drugs, the company's scientists will work to develop compounds and team up with larger pharmaceutical companies to develop them into new treatments for China and the global market.
The new arrangement will make Ascletis the first company of its kind based in both China and the Triangle.
The president and CEO of Ascletis, Jinzi J. Wu, a former vice president of global HIV drug discovery at GlaxoSmithKline, will manage the facilities in both countries. The company's top management will be based in the Triangle but the majority of scientists will work from China.
Hamner had previously been working with Chinese businesses and a medical research park in China to develop and test new medicines in both countries.
This new arrangement was formally established through a Memorandum of Understanding signed by Governor Bev Perdue and Mr. Zhao Hongzhu, Party Secretary of Zhejiang Province and Chairman of the Standing Committee of Zhejiang Provincial People's Congress with the goal of fostering economic development and trade.

North Carolina and Chinese officials signed an agreement Tuesday to create a biosciences gateway in Research Triangle Park for pharmaceutical, biotechnology and other businesses that want to expand in either country.
